Nifty
Sensex
:
:
11598.75
38629.63
22.80 (0.20%)
64.75 (0.17%)

Pharmaceuticals & Drugs

Rating :
56/99  (View)

BSE: 524715 | NSE: SUNPHARMA

465.50
-3.05 (-0.65%)
24-Apr-2019 | 9:39AM
  • Day's Open
  • Day's High
  • Day's Low
  • Previous Close
  •  469.10
  •  470.00
  •  463.45
  •  468.55
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  362112
  •  1685.63
  •  679.30
  •  370.20

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 110,873.27
  • 33.47
  • 1
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 111,329.16
  • 0.43%
  • 2.61

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 54.38%
  • 3.73%
  • 7.36%
  • FII
  • DII
  • Others
  • 0.88%
  • 16.38%
  • 17.27%

Chart

Price | P:E | P:BV | EV:EBITDA

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 19.98
  • 10.44
  • -2.05

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 11.50
  • -4.48
  • -7.47

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 1.87
  • -6.99
  • -21.63

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 33.11
  • 39.96
  • 34.68

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 5.60
  • 5.44
  • 3.90

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 18.38
  • 18.90
  • 16.45

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Dec 18
Dec 17
Var%
Sep 18
Sep 17
Var%
Jun 18
Jun 17
Var%
Mar 18
Mar 17
Var%
Net Sales
7,740.19
6,653.23
16.34%
6,937.63
6,650.34
4.32%
7,224.17
6,208.79
16.35%
6,977.10
7,136.96
-2.24%
Expenses
5,587.30
5,199.85
7.45%
5,406.42
5,274.73
2.50%
5,617.47
5,113.14
9.86%
5,293.61
5,589.48
-5.29%
EBITDA
2,152.89
1,453.38
48.13%
1,531.21
1,375.61
11.31%
1,606.70
1,095.65
46.64%
1,683.49
1,547.48
8.79%
EBIDTM
27.81%
21.84%
22.07%
20.68%
22.24%
17.65%
24.13%
21.68%
Other Income
193.06
129.19
49.44%
351.15
254.84
37.79%
199.75
151.98
31.43%
302.75
224.50
34.86%
Interest
144.79
95.33
51.88%
129.53
157.44
-17.73%
130.90
109.42
19.63%
155.38
44.99
245.37%
Depreciation
471.05
339.32
38.82%
426.51
358.65
18.92%
401.64
346.63
15.87%
455.24
338.17
34.62%
PBT
1,730.11
1,147.92
50.72%
111.94
1,114.36
-89.95%
1,273.91
-158.92
-
1,375.62
1,388.82
-0.95%
Tax
270.92
792.52
-65.82%
218.91
111.40
96.51%
163.86
161.78
1.29%
-176.69
44.30
-
PAT
1,459.19
355.40
310.58%
-106.97
1,002.96
-
1,110.05
-320.70
-
1,552.31
1,344.52
15.45%
PATM
18.85%
5.34%
-1.54%
15.08%
15.37%
-5.17%
22.25%
18.84%
EPS
5.18
1.34
286.57%
-0.91
3.80
-
4.09
-1.77
-
5.46
5.10
7.06%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Mar 09
Net Sales
28,879.09
26,415.54
31,308.14
28,108.61
27,392.01
16,080.36
11,299.86
8,019.49
5,727.90
4,007.45
4,272.30
Net Sales Growth
8.37%
-15.63%
11.38%
2.62%
70.34%
42.31%
40.90%
40.01%
42.93%
-6.20%
 
Cost Of Goods Sold
7,800.26
7,318.73
8,164.20
6,170.19
6,732.84
2,777.68
2,076.36
1,647.61
1,460.40
1,098.45
848.40
Gross Profit
21,078.83
19,096.81
23,143.94
21,938.42
20,659.17
13,302.68
9,223.50
6,371.88
4,267.50
2,909.00
3,423.90
GP Margin
72.99%
72.29%
73.92%
78.05%
75.42%
82.73%
81.62%
79.45%
74.50%
72.59%
80.14%
Total Expenditure
21,904.80
20,880.73
21,625.92
19,950.29
19,615.54
9,120.95
6,437.76
4,836.43
3,785.07
2,644.63
2,408.35
Power & Fuel Cost
-
559.97
525.09
545.44
560.77
232.41
187.10
145.65
96.78
91.92
97.77
% Of Sales
-
2.12%
1.68%
1.94%
2.05%
1.45%
1.66%
1.82%
1.69%
2.29%
2.29%
Employee Cost
-
5,367.05
4,902.30
4,772.31
4,502.64
2,074.44
1,534.53
1,187.73
818.95
396.84
336.65
% Of Sales
-
20.32%
15.66%
16.98%
16.44%
12.90%
13.58%
14.81%
14.30%
9.90%
7.88%
Manufacturing Exp.
-
1,401.09
1,293.98
1,418.59
1,433.89
815.49
618.43
462.65
338.40
398.53
464.82
% Of Sales
-
5.30%
4.13%
5.05%
5.23%
5.07%
5.47%
5.77%
5.91%
9.94%
10.88%
General & Admin Exp.
-
3,288.76
3,113.67
2,956.85
2,894.97
978.48
793.38
629.48
480.66
215.47
144.49
% Of Sales
-
12.45%
9.95%
10.52%
10.57%
6.08%
7.02%
7.85%
8.39%
5.38%
3.38%
Selling & Distn. Exp.
-
1,864.55
2,520.64
2,262.35
2,236.40
1,394.78
763.01
516.55
372.14
290.33
388.60
% Of Sales
-
7.06%
8.05%
8.05%
8.16%
8.67%
6.75%
6.44%
6.50%
7.24%
9.10%
Miscellaneous Exp.
-
1,080.58
1,106.04
1,824.56
1,254.03
847.67
464.95
246.76
217.74
153.09
388.60
% Of Sales
-
4.09%
3.53%
6.49%
4.58%
5.27%
4.11%
3.08%
3.80%
3.82%
2.99%
EBITDA
6,974.29
5,534.81
9,682.22
8,158.32
7,776.47
6,959.41
4,862.10
3,183.06
1,942.83
1,362.82
1,863.95
EBITDA Margin
24.15%
20.95%
30.93%
29.02%
28.39%
43.28%
43.03%
39.69%
33.92%
34.01%
43.63%
Other Income
1,046.71
912.08
1,030.20
658.25
637.89
592.59
422.23
492.77
375.08
211.48
214.36
Interest
560.60
517.57
399.80
523.24
578.99
44.19
43.16
28.20
73.88
6.15
5.85
Depreciation
1,754.44
1,499.84
1,264.75
1,037.53
1,194.72
409.23
336.17
291.16
204.85
153.31
123.29
PBT
4,491.58
4,429.48
9,047.87
7,255.80
6,640.65
7,098.58
4,905.00
3,356.47
2,039.18
1,414.84
1,949.17
Tax
477.00
845.19
1,211.57
913.77
914.69
702.17
845.55
313.19
128.58
67.86
71.16
Tax Rate
10.62%
24.29%
13.39%
13.91%
14.29%
15.33%
19.57%
9.33%
6.31%
4.80%
3.65%
PAT
4,014.58
2,186.99
6,954.44
4,544.26
4,551.94
3,141.47
2,989.59
2,657.80
1,819.29
1,351.08
1,817.73
PAT before Minority Interest
3,336.84
2,633.79
7,836.30
5,656.86
5,488.21
3,879.00
3,475.87
3,043.28
1,910.60
1,346.98
1,878.01
Minority Interest
-677.74
-446.80
-881.86
-1,112.60
-936.27
-737.53
-486.28
-385.48
-91.31
4.10
-60.28
PAT Margin
13.90%
8.28%
22.21%
16.17%
16.62%
19.54%
26.46%
33.14%
31.76%
33.71%
42.55%
PAT Growth
68.53%
-68.55%
53.04%
-0.17%
44.90%
5.08%
12.48%
46.09%
34.65%
-25.67%
 
Unadjusted EPS
13.82
9.00
29.00
18.90
18.90
15.20
14.40
25.70
17.50
13.00
87.80

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Mar 09
Shareholder's Funds
38,100.56
36,639.67
32,982.48
25,638.09
18,524.95
14,989.73
12,235.78
9,483.32
7,828.91
7,044.92
Share Capital
239.93
239.93
240.66
207.12
207.12
103.56
103.56
103.56
103.56
103.56
Total Reserves
37,860.63
36,397.10
32,736.26
25,374.38
18,317.83
14,886.17
12,132.22
9,379.76
7,725.35
6,941.36
Non-Current Liabilities
259.98
599.87
2,169.59
2,335.46
1,748.41
199.02
-225.23
-188.27
82.11
110.99
Secured Loans
217.69
185.59
7.73
40.69
43.76
41.90
49.65
4.38
100.35
36.38
Unsecured Loans
1,554.40
1,250.49
3,102.57
1,327.73
4.91
73.36
105.77
152.90
70.80
142.51
Long Term Provisions
404.46
1,211.11
1,895.86
2,532.34
2,601.62
787.06
138.73
13.00
0.00
0.00
Current Liabilities
19,864.32
17,887.02
13,143.96
16,146.81
5,989.59
2,841.25
2,618.49
1,730.88
757.92
719.81
Trade Payables
4,766.20
4,395.39
3,582.92
3,286.54
1,328.26
1,057.99
992.72
645.38
319.44
254.34
Other Current Liabilities
1,875.93
2,673.68
1,134.27
2,279.59
260.41
218.65
363.66
362.42
90.07
122.37
Short Term Borrowings
7,979.70
6,654.92
5,206.12
6,227.92
2,440.34
82.95
109.57
207.78
0.00
0.00
Short Term Provisions
5,242.49
4,163.03
3,220.65
4,352.76
1,960.58
1,481.66
1,152.54
515.30
348.41
343.10
Total Liabilities
62,109.02
58,917.42
52,381.28
46,971.55
28,184.13
19,665.08
15,790.49
11,873.08
8,862.13
8,072.76
Net Block
18,852.65
17,675.17
15,872.25
12,682.47
6,817.28
5,647.47
3,951.35
3,293.35
1,938.82
1,787.88
Gross Block
26,948.81
24,466.42
22,180.41
20,406.89
10,485.12
8,709.22
6,448.66
5,319.27
2,740.07
2,472.95
Accumulated Depreciation
8,096.16
6,791.25
6,308.16
7,724.42
3,667.84
3,061.75
2,497.31
2,025.92
801.25
685.07
Non Current Assets
30,473.12
25,963.77
22,439.98
18,055.80
9,497.56
8,161.89
5,496.96
4,279.84
3,567.95
3,004.28
Capital Work in Progress
2,465.16
2,801.38
2,175.45
2,038.61
841.54
562.61
344.65
235.46
144.82
157.10
Non Current Investment
3,052.25
961.00
1,116.07
598.87
787.56
1,106.35
588.96
346.01
1,484.31
1,059.30
Long Term Loans & Adv.
6,052.97
3,844.04
2,322.87
2,631.91
1,016.98
802.56
593.29
377.27
0.00
0.00
Other Non Current Assets
50.09
682.18
953.34
103.94
34.20
42.90
18.71
27.75
0.00
0.00
Current Assets
31,635.90
32,953.65
29,941.30
28,915.75
18,686.46
11,503.03
10,293.37
7,593.05
5,294.18
5,068.48
Current Investments
4,090.62
230.88
713.81
2,117.43
1,998.46
1,305.22
1,623.91
1,883.75
1,682.07
800.19
Inventories
6,880.69
6,832.81
6,422.54
5,667.99
3,123.01
2,577.76
2,086.98
1,489.48
1,073.85
975.70
Sundry Debtors
7,815.28
7,202.61
6,775.66
5,106.13
2,200.42
2,412.23
2,078.74
1,104.87
1,174.77
881.09
Cash & Bank
9,929.38
15,140.84
13,181.65
10,998.04
7,590.15
4,058.71
3,367.19
2,204.63
508.89
1,669.03
Other Current Assets
2,919.93
718.25
530.51
3,105.64
3,774.42
1,149.11
1,136.55
910.32
854.60
742.47
Short Term Loans & Adv.
2,028.62
2,828.26
2,317.13
1,920.52
1,093.74
952.93
976.71
784.37
835.09
685.21
Net Current Assets
11,771.58
15,066.63
16,797.34
12,768.94
12,696.87
8,661.78
7,674.88
5,862.17
4,536.26
4,348.67
Total Assets
62,109.02
58,917.42
52,381.28
46,971.55
28,184.13
19,665.08
15,790.49
11,873.08
8,862.13
8,072.76

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Mar 09
Cash From Operating Activity
3,907.15
7,082.21
6,685.86
5,615.74
3,959.20
3,356.58
2,234.46
2,283.10
781.13
2,164.89
PBT
3,478.98
9,047.87
6,570.63
6,402.90
4,581.17
4,314.89
3,355.36
2,035.95
1,414.84
1,949.17
Adjustment
1,382.22
500.67
1,856.92
773.61
-40.15
160.00
111.12
-171.18
-23.60
381.77
Changes in Working Capital
-212.31
-409.21
246.77
179.59
207.10
-44.83
-1,005.25
487.65
-435.63
2.94
Cash after chg. in Working capital
4,648.89
9,139.33
8,674.32
7,356.10
4,748.12
4,430.06
2,461.23
2,352.42
955.61
2,333.88
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-741.74
-2,057.12
-1,988.46
-1,740.36
-788.92
-1,073.48
-226.77
-69.32
-174.48
-168.99
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-3,370.81
-4,221.60
-4,371.59
-2,865.74
-2,366.76
-2,635.05
-862.71
-1,847.71
-213.74
-1,773.02
Net Fixed Assets
-714.76
-1,217.15
2,214.23
-4,631.67
-380.81
-341.28
-267.49
-212.50
-114.06
-169.39
Net Investments
978.04
3,038.39
3,504.47
-18,860.43
-2,698.19
120.24
-836.36
450.27
-1,357.10
-751.47
Others
-3,634.09
-6,042.84
-10,090.29
20,626.36
712.24
-2,414.01
241.14
-2,085.48
1,257.42
-852.16
Cash from Financing Activity
-1,539.26
-2,285.39
-1,888.53
-1,186.53
506.57
-664.99
-544.39
-804.19
-346.43
-266.62
Net Cash Inflow / Outflow
-1,002.92
575.22
425.74
1,563.47
2,099.01
56.54
827.36
-368.80
220.96
125.25
Opening Cash & Equivalents
8,642.36
8,031.69
7,183.49
4,358.70
2,069.11
1,752.67
810.49
633.87
451.24
325.99
Closing Cash & Equivalent
7,906.45
8,642.36
8,031.69
7,285.56
4,358.70
2,069.11
1,752.67
810.49
672.20
451.24

Financial Ratios

Consolidated /

Standalone
Description
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Mar 09
Book Value (Rs.)
158.80
152.70
137.03
123.49
89.44
72.37
59.08
45.79
37.80
34.01
ROA
4.35%
14.08%
11.39%
14.60%
16.21%
19.61%
22.00%
18.43%
15.91%
26.75%
ROE
7.05%
22.51%
19.32%
24.89%
23.15%
25.53%
28.02%
22.07%
18.11%
31.21%
ROCE
8.42%
21.48%
18.64%
25.06%
25.46%
31.39%
30.13%
23.60%
18.67%
31.64%
Fixed Asset Turnover
1.03
1.35
1.34
1.79
1.70
1.51
1.38
1.44
1.57
2.06
Receivable days
103.47
80.78
76.12
48.20
51.72
71.46
71.49
71.57
91.85
95.89
Inventory Days
94.48
76.61
77.46
57.99
63.92
74.22
80.31
80.48
91.57
72.94
Payable days
92.31
77.57
75.24
52.05
56.33
65.15
64.51
51.06
42.23
38.20
Cash Conversion Cycle
105.64
79.82
78.34
54.14
59.31
80.53
87.29
100.98
141.19
130.62
Total Debt/Equity
0.27
0.27
0.26
0.35
0.14
0.02
0.03
0.04
0.02
0.03
Interest Cover
7.72
23.63
13.56
12.06
104.67
101.13
120.02
28.60
231.06
334.19

News Update


  • Sun Pharma's arm to commence distribution of its formulation products in India
    9th Apr 2019, 12:04 PM

    This phased transition is expected to be fully completed by the first quarter of 2019-20

    Read More
  • Sun Pharma launches INFUGEM in US
    8th Apr 2019, 09:13 AM

    INFUGEM is an alcohol-free, clear, colorless, sterile solution of 10mg/mL gemcitabine in 0.9% sodium chloride

    Read More
  • Sun Pharma receives observation from USFDA for plant in Gujarat
    25th Mar 2019, 16:24 PM

    The USFDA had conducted a PAI of Baska facility from January 28 to February 5, 2019

    Read More
  • Sun Pharma’s arm acquires 11.86% stake in PJSC Biosintez
    13th Mar 2019, 16:19 PM

    The total holding of Sun Pharma (Netherlands) BV was increased from 85.10% to 96.96% in PJSC Biosintez

    Read More
  • Sun Pharma’s arm collaborates with HitGen
    13th Mar 2019, 14:25 PM

    The collaboration aims to identify novel small molecule leads for targets of interest

    Read More
  • Sun Pharma reports around 4-fold jump in Q3 consolidated net profit
    13th Feb 2019, 09:35 AM

    Total consolidated income of the company increased by 16.97% at Rs 7,933.25 crore for Q3FY19

    Read More
  • Sun Pharma Inds. - Quarterly Results
    12th Feb 2019, 16:27 PM

    Read More
  • Sun Pharma to replace domestic formulations distributor with its own subsidiary
    22nd Jan 2019, 11:45 AM

    This change will be made effective by Q1FY20, post receipt of all requisite regulatory approvals

    Read More

Source: www.accordfintech.com. Price feed provided by www.nseindia.com and www.bseindia.com value addition by www.accordfintech.com. Intraday data delayed 15 minutes.

DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.